Open label, phase II dosing study of ara-C [cytarabine] chemotherapy in combination with EL625 and idarubicin in refractory and relapsed acute myelogenous leukemia (AML)

Trial Profile

Open label, phase II dosing study of ara-C [cytarabine] chemotherapy in combination with EL625 and idarubicin in refractory and relapsed acute myelogenous leukemia (AML)

Completed
Phase of Trial: Phase II

Latest Information Update: 04 Nov 2014

At a glance

  • Drugs Cenersen (Primary) ; Cytarabine; Idarubicin
  • Indications Acute myeloid leukaemia
  • Focus Therapeutic Use
  • Sponsors Eleos
  • Most Recent Events

    • 29 Jun 2011 Results published in the Cancer.
    • 12 Jul 2007 Status changed from in progress to completed.
    • 07 Sep 2005 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top